Myovant Sciences Ltd (NASDAQ:MYOV) was upgraded by Zacks Investment Research from a “sell” rating to a “hold” rating in a report issued on Thursday.

According to Zacks, “Myovant Sciences Ltd. is a biopharmaceutical company. It focused on developing and commercializing therapies for women’s health diseases and other endocrine-related disorders, including advanced prostate cancer. The company’s product candidate consists of relugolix which are in clinical trial, an oral once-daily small molecule that acts as a gonadotropin-releasing hormone receptor antagonist. Myovant Sciences Ltd. is based in Hamilton, Bermuda. “

Separately, Evercore ISI began coverage on shares of Myovant Sciences in a research note on Wednesday, August 16th. They set an “outperform” rating on the stock. One analyst has rated the stock with a hold rating and six have issued a buy rating to the company. The company has a consensus rating of “Buy” and a consensus price target of $18.20.

Myovant Sciences (NASDAQ:MYOV) opened at 12.37 on Thursday. The firm has a 50-day moving average of $12.05 and a 200 day moving average of $12.05. The firm’s market capitalization is $752.64 million. Myovant Sciences has a 12 month low of $9.92 and a 12 month high of $15.50.

WARNING: This story was first posted by The Cerbat Gem and is the sole property of of The Cerbat Gem. If you are viewing this story on another site, it was illegally copied and reposted in violation of U.S. and international copyright laws. The correct version of this story can be viewed at https://www.thecerbatgem.com/2017/09/09/zacks-investment-research-upgrades-myovant-sciences-ltd-myov-to-hold.html.

Several hedge funds and other institutional investors have recently modified their holdings of the stock. OxFORD Asset Management LLP increased its stake in shares of Myovant Sciences by 15.4% in the second quarter. OxFORD Asset Management LLP now owns 29,745 shares of the company’s stock worth $348,000 after buying an additional 3,971 shares during the period. Bank of New York Mellon Corp increased its stake in shares of Myovant Sciences by 36.3% in the first quarter. Bank of New York Mellon Corp now owns 23,784 shares of the company’s stock worth $279,000 after buying an additional 6,330 shares during the period. Wells Fargo & Company MN increased its stake in shares of Myovant Sciences by 331.9% in the first quarter. Wells Fargo & Company MN now owns 16,527 shares of the company’s stock worth $194,000 after buying an additional 12,700 shares during the period. Quantitative Systematic Strategies LLC purchased a new position in shares of Myovant Sciences in the second quarter worth $165,000. Finally, BB Biotech AG increased its stake in shares of Myovant Sciences by 0.4% in the second quarter. BB Biotech AG now owns 3,317,171 shares of the company’s stock worth $38,811,000 after buying an additional 14,336 shares during the period.

About Myovant Sciences

Myovant Sciences Ltd. is a clinical-stage biopharmaceutical company focused on developing and commercializing therapies for women’s health diseases and other endocrine-related disorders. Its main product candidate is Relugolix. Relugolix is an oral, once-daily, small molecule that acts as a gonadotropin-releasing hormone (GnRH) receptor antagonist that binds to and inhibits receptors in the anterior pituitary gland.

Analyst Recommendations for Myovant Sciences (NASDAQ:MYOV)

Receive News & Stock Ratings for Myovant Sciences Ltd Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Myovant Sciences Ltd and related stocks with our FREE daily email newsletter.